Shelley Jones, MD
Infectious Disease · Wichita, KSNPI 1598752800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations.
Across 92 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$360
- AbbVie$358
- Melinta Therapeutics, LLC$180
- Paratek Pharmaceuticals, Inc.$124
- Hospira, Inc.$92
- Gilead$81
- plus $413 from 12 others
What the payments were for
- Consulting fees$191%
- Food & beverage$1,58298%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 23 | $360 |
| AbbVie(2 entities) | 19 | $358 |
| Melinta Therapeutics, LLC | 12 | $180 |
| Paratek Pharmaceuticals, Inc. | 8 | $124 |
| Hospira, Inc. | 5 | $92 |
| Gilead | 5 | $81 |
| Aimmune Therapeutics, Inc. | 2 | $77 |
| Viiv Healthcare Company | 3 | $57 |
| Pfizer | 2 | $50 |
| Merck | 3 | $42 |
| ADMA Biomanufacturing LLC | 2 | $39 |
| AstraZeneca | 2 | $31 |
| Mayne Pharma Commercial LLC | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Vyera Pharmaceuticals, LLC | 1 | $20 |
| Integra Lifesciences Corporation | 1 | $20 |
| Shionogi Inc | 1 | $17 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$1,607 in reported general payments places this provider in the 75th percentile of 56 infectious disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 74 | $115,509 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $64,694 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $44,908 |
| TivicayDolutegravir Sodium | 12 | $31,126 |
| ErtapenemErtapenem Sodium | 44 | $25,921 |
| CeftriaxoneCeftriaxone Sodium | 59 | $5,321 |
| Methenamine Hippurate | 53 | $2,922 |
| Doxycycline Hyclate | 94 | $2,662 |
| Dicloxacillin Sodium | 22 | $1,927 |
| Vancomycin Hcl | 12 | $1,563 |
| Cefdinir | 35 | $1,530 |
| Cephalexin | 142 | $1,522 |
| Penicillin V Potassium | 88 | $1,071 |
| Linezolid | 13 | $1,013 |
| Minocycline Hcl | 40 | $969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $81 | $44,90812 claims |
| Viiv Healthcare CompanyTivicay | $57 | $31,12612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 56 infectious disease providers in Kansas.
Other infectious disease in Wichita
- Thomas MooreWichita$37K
- Maha AssiWichita$9K
- Margaret HaganWichita$4K
- Garret SeilerWichita$2K
- Keck HartmanWichita$2K
- Jerry PeterieWichita$2K
- Wissam El AtrouniKansas City$15K
- John FriedOverland Park$7K
- Marjorie WongskhaluangLeawood$5K
- Apoorv KalraOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.